SCHEMBL6003329

SCHEMBL6003329

Cn1cc(-c2ccc3c(c2)OCO3)c2onc(-c3ccccc3)c2c1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.60
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MITF O75030 1/20 0.43
PTGS2 P35354 1/20 0.43
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.40
GAA P10253 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5529965 0.90 NR4A2 (0.58) NR4A2NPC1RAB9ACASP3SENP8
SCHEMBL5531593 0.88 NPC1 (0.47) NR4A2NPC1RAB9AMEN1KMT2A
SCHEMBL5538906 0.85 NR4A2 (0.55) NR4A2NPC1RAB9ACASP3SENP8
SCHEMBL2509981 0.75 NR4A2 (1.00) NR4A2NPC1RAB9ACASP3SENP8
SCHEMBL5529958 0.73 NR4A2 (0.76) NR4A2NPC1RAB9ACASP3SENP8
SCHEMBL30083712 0.69 MAPK9 (0.47) NR4A2NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL28937845 0.69 MAPK9 (0.47) NR4A2NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL5538903 0.69 NR4A2 (0.76) NR4A2NPC1RAB9ACASP3SENP8
SCHEMBL31590242 0.66 CECR2 (0.60)
SCHEMBL15452456 0.66 MEN1 (0.56) NR4A2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087756-B2 Isoxazolopyridinones NOVARTIS AG (CH) 2006-08-08 US disclosed
US-20040248893-A1 Isoxazolopyridinones NOVARTIS AG (CH) 2004-12-09 US disclosed
EP-1418912-A2 ISOXAZOLOPYRIDINONES Novartis AG (CH) 2004-05-19 EP disclosed
WO-2003015780-A2 ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE NOVARTIS AG (CH) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248893-A1 Isoxazolopyridinones XDH, NPY1R, TBXA2R NR4A2 2718/4885NPC1 3047/4885RAB9A 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.